Rationale for Collaboration Sample Clauses

Rationale for Collaboration. Latinos make up 6.4% of the Dane County population (2017 Census estimates) and account for the largest ethnic minority (22%) of MMSD students (2018-19 MMSD DPI data). The second fastest-growing racial group in the United States (2% in 2017, Pew Research Center), it is estimated that by 2025 32% of all college applicants will identify as Latino (National Center for Education Statistics). Despite these successes, nationally the Latino population faces countless barriers to achieving academic and career success with a graduation rate of only 77.8% which is 12.2% lower than that of their white peers. In addition, college drop-out rates among Latino young adults remains high, and compared to other demographic groups they are the least likely to earn a bachelor’s degree (21% compared to 45% of their white peers and 32% of their black peers, Georgetown University: Center on Education and the Workforce) The goal of the Juventud and Xxxxxxxx programs is to change this trajectory through improved social support as part of mentoring, tutoring, greater career knowledge, cultural awareness, and efforts from Centro Hispano staff to better engage parents in their students’ academic achievement. Our vision is that Latino middle and high school students in Madison improve their academic performance, graduate on time, and increase their possibilities to attend college while creating a strong sense of identity. One of the goals of MMSD is to ensure that every student is on-track to graduate as measured by student growth and achievement at key milestones. The achievement milestone identified for middle school is “high school readiness in grade 8” and “college readiness in grade 11, high school graduation and completion” for high school. Juventud and Xxxxxxxx directly support this goal by providing in-school and after-school tutoring support and supplemental activities focused on improving academic performance and preparing students for college. Further, this partnership supports the goals and priorities outlined in MMSD’s Strategic Framework 2018; Goals 1 and 2, and Xxxxx 3: Positive, trusting relationships that xxxxxx safe and thriving cultures and climates.

Rationale for Collaboration. Significant numbers of students of color and those from low-income families are not performing at grade level during their elementary years. UWDC and Centro have long-standing and deep commitments to assuring that every child reaches his or her highest academic potential and to mobilizing the community to provide direct support to students in partnership with Dane County school districts. MMSD, UWDC and Centro are committed to working collaboratively with other partners to ensure alignment with partners’ missions: • MMSD’s Strategic Framework Goals: “Every student is on track to graduate as measured by student growth and achievement at key milestones” including: reading by grade 3 and proficiency in reading and math in grade 5) • MMSD’s Strategic Framework Priority Areas: Priority Area 1: Coherent Instruction, and Priority Area 3: Family Engagement and Community Partnerships; • UWDC’s Agenda for Change for Education: “Students succeed academically and graduate from high school, regardless of race.” “Increase the proportion of students of color who score proficient or advanced on the Fourth Grade Reading Test.” • Centro’s mission: “To xxxxxx thriving Dane County youth, families and community by improving the quality of life for Latinos in the region through high-quality programming and services.”

Rationale for Collaboration. UWDC and ULGM have long-standing and deep commitments to assuring that every child graduates from high school and transitions to career and life success as an adult. As community partners to MMSD, we work to mobilize the community to provide direct tutoring and coaching to students to achieve their goals. One of the goals of MMSD is to ensure that every student is on-track to graduate as measured by student growth and achievement at key milestones. The achievement milestone identified for middle school is high school readiness at the conclusion of grade 8. SOH MS directly supports this goal by providing in-school and after-school tutoring support focused on improving the literacy and math achievement of underperforming middle school students. MMSD, ULGM and UWDC are committed to working collaboratively to ensure alignment with MMSD’s Strategic Framework (“Every student is on track to graduate as measured by student growth and achievement at key milestones”); Goal 3 (Black Excellence); UWDC’s Agenda for Change for Education (“Students succeed academically and graduate from high school, regardless of race.”)

Rationale for Collaboration. Latinos under the age of 30 are one of the fastest growing segments of the Dane County population. In Madison, Census statistics estimate that the Latino population has increased from 4.1% in 2000 to 6.9% in 2010. This increase is particularly pronounced in neighborhoods on the South side of Madison where in 2013 over half of the incoming kindergarten class at Leopold School will be Latino. Unfortunately, nationally the Latino population faces countless barriers to achieving academic and career success with dropout rates that are alarmingly high. According to the National Council of La Raza, 28% of Latino students, ages 16-24, permanently drop out of public high school and more than a third are unemployed. Traditionally, Latinos who are employed are concentrated in low-income, low-wage jobs. The goal of the Juventud and Xxxxxxxx programs is to change this trajectory through improved social support as part of mentored tutoring sessions, greater career knowledge, cultural awareness, and efforts from Centro Hispano staff to better engage parents in their students’ academic achievement. Our vision is that Latino middle and high school students in Madison improve their academic performance, graduate on time, and increase their possibilities to attend college while creating a strong sense of identity. One of the goals of MMSD is to ensure that every student is on-track to graduate as measured by student growth and achievement at key milestones. The achievement milestone identified for middle school is “high school readiness in grade 8” and “college readiness in grade 11, high school graduation and completion” for high school. Juventud and Xxxxxxxx directly support this goal by providing in-school and after-school tutoring support and supplemental activities focused on improving academic performance and preparing students for college. Further, this partnership aligns directly with MMSD’s Strategic Framework, Priority Area 1: Coherent Instruction and Priority Area 3: Family Engagement and Community Partnerships: align community partners to district goals and priorities with a focus on our areas of highest need.

Related to Rationale for Collaboration

Research Collaboration 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, AxxxXxxx decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 Within [***] ([***]) days after completion of the [***], Aarvik shall deliver to ArriVent a full report on all key results and findings of the Collaboration Program, and such other data, results and information as ArriVent may deem necessary for it to determine whether or not to exercise the Option (the “Full Report”).
Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services
Scope of Collaboration As part of the collaboration, the Controllers will act as Joint Controller. The roles of the Controller and the associated tasks are specified in more detail in Appendix 1. If one party is solely responsible for a data processing operation, this party will implement all relevant data protection provisions on its own responsibility. However, such data processing procedures are not subject to this Agreement. Joint data processing and the type of Personal Data collected and processed within the framework of collaboration are specified in Appendix 1.
Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.
Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).
Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.
Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.
Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.
Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.
Commercialization Efforts The RECIPIENT shall, including whether through its own efforts or the efforts of a licensee under a License Agreement allowed by the terms of this Attachment, use diligent and commercially reasonable efforts to commercialize at least one Commercial Product or Commercial Service or otherwise bring to practical application the Project Results in accordance with the commercial development plan submitted with the Application and including any changes to such commercial development plan in accordance with Section D3.01. For the avoidance of doubt, partnering or licensing activities shall be considered to be efforts to commercialize.

Rationale for Collaboration Sample Clauses

Filter & Search

Related Clauses

Related to Rationale for Collaboration